Halozyme Therapeutics, Inc. Comprehensive Income 2010-2024 | HALO

Halozyme Therapeutics, Inc. comprehensive income for the quarter ending June 30, 2024 was $-0.002B, a 28.05% increase year-over-year.

  • Halozyme Therapeutics, Inc. comprehensive income for 2023 was $-0.009B, a 906.29% increase from 2022.
  • Halozyme Therapeutics, Inc. comprehensive income for 2022 was $-0.001B, a 48.71% increase from 2021.
  • Halozyme Therapeutics, Inc. comprehensive income for 2021 was $-0.001B, a 2918.18% decline from 2020.

Halozyme Therapeutics, Inc. Comprehensive Income 2010-2024 | HALO

  • Halozyme Therapeutics, Inc. comprehensive income for 2023 was $-0.009B, a 906.29% increase from 2022.
  • Halozyme Therapeutics, Inc. comprehensive income for 2022 was $-0.001B, a 48.71% increase from 2021.
  • Halozyme Therapeutics, Inc. comprehensive income for 2021 was $-0.001B, a 2918.18% decline from 2020.
Related Stocks
Company NameMarket
Cap
Amgen (AMGN)$174.8B
Vertex Pharmaceuticals (VRTX)$133.1B
Gilead Sciences (GILD)$120.2B
Bristol Myers Squibb (BMY)$109.8B
Regeneron Pharmaceuticals (REGN)$91B
CSL (CSLLY)$90.5B
GSK (GSK)$75.2B
Alnylam Pharmaceuticals, Inc. (ALNY)$35.8B
argenex SE (ARGX)$35.6B
BioNTech SE Sponsored ADR (BNTX)$26.3B
Biogen Inc. (BIIB)$25.2B
Illumina, Inc. (ILMN)$24B
BeiGene, Ltd. (BGNE)$20B
Moderna, Inc. (MRNA)$18B
Incyte Corporation (INCY)$16.1B
Genmab A/S Sponsored ADR (GMAB)$15.3B
Vaxcyte, Inc. (PCVX)$13.3B
Insmed, Inc. (INSM)$13.2B
BioMarin Pharmaceutical Inc. (BMRN)$12.8B
Bio-Techne Corp (TECH)$12.1B
Sarepta Therapeutics, Inc. (SRPT)$11.6B
Exelixis, Inc. (EXEL)$10.4B
Revolution Medicines, Inc. (RVMD)$10.2B
QIAGEN N.V. (QGEN)$10B
Intra-Cellular Therapies Inc. (ITCI)$9.7B
Exact Sciences Corporation (EXAS)$9.5B
Bio-Rad Laboratories, Inc. (BIO.B)$9.4B
Roivant Sciences Ltd. (ROIV)$8.8B
Repligen Corporation (RGEN)$7.9B
Viking Therapeutics, Inc. (VKTX)$7.6B